RRx-001 | MedChemExpress (MCE)

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

RRx-001

CAS No. : 925206-65-1

MCE 国际站：RRx-001

产品活性：RRx-001 是一种低氧选择性的表观遗传因子，被用作放射或化疗敏感剂，能诱发凋亡，克服骨髓瘤的耐药性。RRx-001 具有有效的抗癌活性且毒性极低。RRx-001是一个免疫检查点的抑制剂，可下调 CD47 和SIRP-α。RRx-001是G6PD的有效抑制剂，具有较强的抗疟活性。

研究领域：Apoptosis  |  Anti-infection

作用靶点：Apoptosis  |  Parasite

In Vitro: RRx-001 (0-5 μM, 24 hours) inhibits MM cells growth and overcomes resistance to novel and conventional therapies.
RRx-001 blocks migration of MM cells and associated angiogenesis.
RRx-001 induces significant G1 phase growth arrest, with a concomitant decrease in the S phase. RRx-001 triggers significant apoptosis in MM cells.
RRx-001 inhibits DNA methylation by downregulating DNA methytransferases.
RRx-001 and the supernatant of RRx-001-treated macrophages downregulates CD47 on tumor cells and SIRPα on macrophages.

In Vivo: RRx-001 (5 mg/kg or 10 mg/kg, I.V., thrice-weekly for 24 days) inhibits tumor growth and prolongs survival in a xenograft mouse model.
RRx-001 (10 mg/kg, IP, twice a week and once a day) exhibits potent anti-cancer activity on the A549 lung cancer model dependent on the presence of tumor-associated macrophages (TAMs) in tumor tissue.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Antiparasitic Compound library  |  Anti-Cancer Metabolism Compound Library  |  Rare Diseases Drug Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  Cell Death Library  |  Anti-Drug-Resistant Compound Library  |  Anti-Hematopathy Compound Library  |  MG-132  |  Chloroquine  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Tamoxifen  |  Y-27632  |  LY294002  |  Paclitaxel  |  Acetylcysteine  |  Angiotensin II human  |  2-Deoxy-D-glucose  |  Puromycin dihydrochloride  |  Staurosporine  |  Actinomycin D  |  SB-431542  |  5-Fluorouracil  |  Bortezomib  |  Deferoxamine mesylate  |  Oxaliplatin  |  Trametinib  |  Sorafenib  |  Temozolomide  |  Gemcitabine  |  Decitabine  |  Mdivi-1  |  Elesclomol  |  Rotenone  |  Etoposide  |  Ruxolitinib  |  SP600125

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。